These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1833294)

  • 1. [Pharmacological effects of the novel dopamine uptake inhibitor 1-[2-[bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on the central nervous system].
    Nagase T; Hotta K; Morita S; Sakai K; Yamane M; Omote M; Mizusawa H
    Nihon Yakurigaku Zasshi; 1991 Aug; 98(2):121-41. PubMed ID: 1833294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of 1-[2-[bis(fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on turnover of dopamine and norepinephrine in the brain].
    Nagase T; Ishiko J; Takaori S
    Nihon Yakurigaku Zasshi; 1987 Aug; 90(2):105-14. PubMed ID: 3119439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
    Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
    Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thyrotropin-releasing hormone (TRH): Enhancement of dopamine dependent circling behavior and its own circling-inducing effect in unilateral striatal lesioned animals (author's transl)].
    Fukuda N; Miyamoto M; Narumi S; Nagai Y; Shima T; Nagawa Y
    Nihon Yakurigaku Zasshi; 1979 Apr; 75(3):251-70. PubMed ID: 231554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of mafoprazine, a phenylpiperazine derivative, on the central dopaminergic system.
    Yamamura M; Nakagawa H; Maeda K; Kinoshita K; Ishida R
    Jpn J Pharmacol; 1989 Jul; 50(3):295-305. PubMed ID: 2569544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GBR 13098, a selective dopamine uptake inhibitor; behavioural, biochemical and electrophysiological studies.
    Pileblad E; Engberg G
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Dec; 334(4):383-7. PubMed ID: 2950328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions.
    Kurumiya S; Miura Y; Nakatsuji K; Dodo M; Hori M; Ito T
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of suloctidil on the central and peripheral nervous systems].
    Nishi H; Watanabe T; Mori M
    Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake.
    Heikkila RE; Manzino L
    Eur J Pharmacol; 1984 Aug; 103(3-4):241-8. PubMed ID: 6237922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents.
    Ikawa K; Watanabe A; Kaneno S; Toru M
    Eur J Pharmacol; 1993 Dec; 250(2):261-6. PubMed ID: 7906653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptake inhibitor, in mice.
    Hirate K; Kuribara H
    Jpn J Pharmacol; 1991 Apr; 55(4):501-11. PubMed ID: 1832199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of 1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl)ethanol dihydrochloride (NC-1100) on the central nervous system].
    Tanabe K; Kinoshita Y; Tokuyoshi K; Houri D; Kimishima K
    Nihon Yakurigaku Zasshi; 1991 Nov; 98(5):357-68. PubMed ID: 1813367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of GBR 12909 on locomotor activity and dopamine turnover in mice: comparison with apomorphine.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1995 Jan; 272(1):79-85. PubMed ID: 7713153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phencyclidine and related compounds evoked [3H]dopamine release from rat mesencephalic cell cultures by a mechanism independent of the phencyclidine receptor, sigma binding site, or dopamine uptake site.
    Mount H; Boksa P; Chaudieu I; Quirion R
    Can J Physiol Pharmacol; 1990 Sep; 68(9):1200-6. PubMed ID: 1980428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs.
    Desai RI; Kopajtic TA; French D; Newman AH; Katz JL
    J Pharmacol Exp Ther; 2005 Oct; 315(1):397-404. PubMed ID: 16014753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S; Toba Y; Suzuki S; Ninomiya S; Umezato M; Hiyama T
    Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (5) Action of M73101 on the central nervous system (author's transl)].
    Sato M
    Nihon Yakurigaku Zasshi; 1979 Oct; 75(7):695-706. PubMed ID: 575516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.